CNMAU-8 is under clinical development by Clene and currently in Phase III for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase III drugs for Amyotrophic Lateral Sclerosis have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how CNMAU-8’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CNMAU-8 overview
CNMAU-8 is under development for the treatment of relapsing multiple sclerosis, chronic optic neuropathy associated with primary progressive multiple sclerosis or non-active secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, neuronal aging-related deficits, Alzheimer’s disease and rett syndrome. The drug candidate nanocrystalline gold suspension formulated as a nanosuspension. It is administered through oral route. It is a small molecule developed based on Clean-Surface Nanosuspension (CSN) technology.
It was also under development for amyotrophic lateral sclerosis, relapsing-remitting multiple sclerosis and Parkinson's disease
Clene overview
Clene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. It is headquartered in Salt Lake City, Utah, the US.
For a complete picture of CNMAU-8’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
